MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

NCT01294306 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

NIH

Sponsor class

Conditions

Adenosquamous Lung Carcinoma
Bronchioloalveolar Carcinoma
Large Cell Lung Carcinoma
Lung Adenocarcinoma
Recurrent Non-Small Cell Lung Carcinoma
Squamous Cell Lung Carcinoma

Interventions

DRUG: Akt Inhibitor MK2206
DRUG: Erlotinib Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)